IDEAYA Biosciences lost $125.7 million last quarter, with $10.2 million in revenue from a licensing deal.

Nov 3, 2026, 7:47 AM ETResultsRead the original at prnewswire.com

Good for IDYA

IDEAYA completed its drug application for darovasertib and says its cash can fund work into 2030. Revenue was $10.2 million, mainly from license services, and its loss was $125.7 million, but the progress and runway support a positive read.

IDYA · IDEAYA Biosciences, Inc.

AI read · Good for IDYA

The AI's read

The completed application brings darovasertib closer to a possible use for metastatic eye cancer. IDEAYA also says its cash can fund work into 2030. The reported loss and service-driven revenue are concerns, but they do not erase the application progress and funding runway.

Get alerts for IDYA

Follow IDEAYA Biosciences, Inc. (IDYA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IDYA

Free on the App Store and Google Play, or on the web.